EUCTR2005-001556-20-DK进行中（未招募）不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent prior to beginning study-related procedures (subject must understand the aims, investigational procedures and possible consequences of the study).
- •2. Male or female aged 18 to 80 years of age at screening. Female subjects of
- •childbearing potential must be willing to follow contraceptive measures (described in
- •Appendix 3 of study protocol).
- •3. Successful percutaneous coronary intervention (PCI) defined as placement of bare
- •metal or drug eluting stent in the native coronary arteries
- •Uncomplicated diagnostic cardiac catheterization in subjects in whom no PCI is
- •Important: approximately =50% of randomized subjects must present with ACS and
- •evidence of myocardial necrosis (i.e., STEMI or NSTEMI). ACS is defined as a history
- •of chest pain (or chest pain equivalent) lasting = 20 minutes that occurred within 72 hours prior to the qualifying IVUS and the presence of elevated concentrations of cardiac biomarkers (troponins). Pre-catheterization Troponin must be assessed at both central and local laboratories and determined to be >99th percentile of the values for a reference control group to qualify as evidence of myocardial necrosis. The central laboratory Troponin I value will be used for the purpose of analyses.
- •4. Baseline IVUS of the non-intervened coronary arterial segment recorded according
- •to protocol-mandated criteria that contains a lesion with less than 50% stenosis by
- •visual inspection on angiography (refer to IBIS-2 Study Manual: – Imaging Procedures and Measurements [Core Imaging Laboratory, 2005])
- •5. Must be receiving at least one oral antiplatelet agent (e.g., aspirin, clopidogrel) at
- •time of randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinical and laboratory exclusion criteria:
- •1. Evidence of clinical instability or new abnormal clinical laboratory findings post-PCI
- •or post cardiac catheterization but prior to randomization that in opinion of the
- •investigator makes the subject unsuitable for the study.
- •2. History of CABG surgery.
- •3. Planned cardiac surgery (e.g., CABG, valve repair or replacement) or planned major
- •non-cardiac surgery within the study period.
- •4. Stroke or resuscitated cardiac arrest in the past 6 months.
- •5. QTc interval >440msec (males) or >450msec (females) at Screening
- •6. History of chronic viral hepatitis (including hepatitis B surface antigen or hepatitis C
- •antibody) or other chronic hepatic disorder. ALT or AST >2.5 x upper limit of normal or alkaline phosphatase or total bilirubin >1.5 x upper limit of normal at Screening.
- •7. Renal impairment with serum creatinine >2.0 mg/dL (177umol/L) or calculated creatinine clearance <40 mL/min/1.73 m2 at Screening (based on MDRD Study equation [Levey, 1999]), or history of kidney transplant, or history of contrast nephropathy.
- •8. Current inadequately controlled hypertension (blood pressure >160 mmHg systolic
- •and/or >100 mmHg diastolic) on a stable dose of antihypertensive medication.
- •9. Recent use (within < 1 month) or currently receiving transdermal, oral, inhaled, or
- •injectable corticosteroids.
- •10. Current poorly controlled diabetes mellitus, defined as HbA1c >10% at Screen.
- •11. History of severe heart failure defined as NYHA class III or IV or known severe left ventricular (LV) dysfunction (ejection fraction [EF]<30%) regardless of symptomatic status.
- •12. History of adult asthma manifested by bronchospasm in the past 6 months, or
- •currently taking regular anti-asthmatic medication(s).
- •13. History of anaphylaxis, anaphylactoid reactions or severe allergic responses within the past 6 months.
- •14. History of malignancy within the past 5 years, other than non-melanoma skin cancer.
- •15. Current life-threatening condition other than vascular disease (e.g., very severe
- •chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent
- •a subject from completing the study.
- •16. Alcohol or drug abuse within the past 6 months.
- •17. Currently receiving oral or injectable potent CYP3A4 inhibitor(s). Subjects should be instructed to refrain from consumption of > 240mL daily of grapefruit-juice, which may inhibit CYP3A4.
- •18. Previous exposure to SB-480848.
- •19. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.
- •20. Pregnancy (defined as a positive pregnancy test by serum ß-HCG) or lactation at
- •21. Any subject the investigator deems unsuitable for the study (e.g., due to medical
- •reasons, laboratory abnormalities, expected study medication noncompliance, or unwillingness or inability to comply with all study-related procedures).
- •Anatomical exclusion criteria:
- •22. Left main coronary artery stenosis >50% by visual inspection of coronary angiogram.
- •23. Luminal diameter of the study vessel <2.5 mm by visual inspection of coronary
- •24. Severe tortuousity of the study vessel or any other relevant anatomical reasons (e.g., heavy calcifications) that the investigator deems inappropriate for IVUS study.
研究者
相似试验
进行中（未招募）
不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-CZGlaxoSmithKline Research & Development Limited300
进行中（未招募）
1 期
Integrated Biomarker and Imaging Study – 2 (IBIS-2)Estudio integrado de biomarcadores y técnicas de imagen - 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-ESGlaxoSmithKline, S.A.
进行中（未招募）
不适用
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2EUCTR2005-001556-20-ATGlaxoSmithKline Research & Development Limited300
进行中（未招募）
1 期
Integrated Biomarker and Imaging Study – 2 (IBIS-2) - IBIS-2SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.EUCTR2005-001556-20-GBGlaxoSmithKline Research & Development Limited
招募中
不适用
Biomarker and Imaging Study to assess the ability of high doses rosuvastatin to decrease artherosclerosis in coronary arteries.Coronary artery diseaseNL-OMON24500Erasmus Medical center (Thoraxcenter)300